Education
About Us
Working with TipRanks
Follow Us
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
Total Valuation
Virax Biolabs Group Ltd. Class A has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,341,956
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Virax Biolabs Group Ltd. Class A’s return on equity (ROE) is -1.06 and return on invested capital (ROIC) is -103.22%.
Return on Equity (ROE)-1.06
Return on Assets (ROA)-0.94
Return on Invested Capital (ROIC)-103.22%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee372.41
Profits Per Employee-356.90K
Employee Count17
Asset Turnover<0.01
Inventory Turnover0.63
Valuation Ratios
The current PE Ratio of Virax Biolabs Group Ltd. Class A is ―. Virax Biolabs Group Ltd. Class A’s PEG ratio is 0.01.
PE Ratio―
PS Ratio557.69
PB Ratio0.62
Price to Fair Value0.62
Price to FCF-0.68
Price to Operating Cash Flow-0.61
PEG Ratio0.01
Income Statement
In the last 12 months, Virax Biolabs Group Ltd. Class A had revenue of 6.33K and earned -6.06M in profits. Earnings per share was -1.96.
Revenue6.33K
Gross Profit-53.07K
Operating Income-6.16M
Pretax Income-6.20M
Net Income-6.06M
EBITDA-5.80M
Earnings Per Share (EPS)-1.96
Cash Flow
In the last 12 months, operating cash flow was -4.56M and capital expenditures -603.89K, giving a free cash flow of -5.17M billion.
Operating Cash Flow-4.56M
Free Cash Flow-5.17M
Free Cash Flow per Share-1.19
Dividends & Yields
Virax Biolabs Group Ltd. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.34
52-Week Price Change-61.90%
50-Day Moving Average0.65
200-Day Moving Average1.11
Relative Strength Index (RSI)49.45
Average Volume (3m)315.79K
Important Dates
Virax Biolabs Group Ltd. Class A upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Virax Biolabs Group Ltd. Class A as a current ratio of 7.27, with Debt / Equity ratio of 6.62%
Current Ratio7.27
Quick Ratio7.13
Debt to Market Cap<0.01
Net Debt to EBITDA0.66
Interest Coverage Ratio-105.93
Taxes
In the past 12 months, Virax Biolabs Group Ltd. Class A has paid -136.66K in taxes.
Income Tax-136.66K
Effective Tax Rate0.02
Enterprise Valuation
Virax Biolabs Group Ltd. Class A EV to EBITDA ratio is 0.06, with an EV/FCF ratio of 0.06.
EV to Sales-50.74
EV to EBITDA0.06
EV to Free Cash Flow0.06
EV to Operating Cash Flow0.07
Balance Sheet
Virax Biolabs Group Ltd. Class A has $4.23M in cash and marketable securities with $377.00K in debt, giving a net cash position of $3.85M billion.
Cash & Marketable Securities$4.23M
Total Debt$377.00K
Net Cash$3.85M
Net Cash Per Share$0.89
Tangible Book Value Per Share$1.75
Margins
Gross margin is -838.21%, with operating margin of -97344.76%, and net profit margin of -95739.17%.
Gross Margin-838.21%
Operating Margin-97344.76%
Pretax Margin-97992.31%
Net Profit Margin-95739.17%
EBITDA Margin-91649.46%
EBIT Margin-97073.35%
Analyst Forecast
The average price target for Virax Biolabs Group Ltd. Class A is ―, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target―
Price Target Upside―
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―